Interaction of nuclear receptor ligands with the Vitamin D signaling pathway in prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 92, Issue 4, 2004, Pages 307-315

  Peehl, Donna M ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glucocorticoids; IGFBP 3; Nuclear receptors; Prostate cancer; Retinoids; Vitamin D

Indexed keywords

ALITRETINOIN; ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CALCITRIOL; CORTICOSTEROID; CORTICOSTERONE; DEOXYCORTICOSTERONE; DEXAMETHASONE; DOCETAXEL; ESTROGEN RECEPTOR; FENRETINIDE; GLUCOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; RETINOIC ACID; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOID X RECEPTOR ALPHA; RO 245531; SR 11238; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANDROGEN SYNTHESIS; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; DOWN REGULATION; DRUG DOSE REGIMEN; DRUG SCREENING; HUMAN; HYPERCALCEMIA; LIGAND BINDING; NONHUMAN; PROSTATE CANCER; RECEPTOR UPREGULATION; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ANDROGENS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; DRUG INTERACTIONS; GLUCOCORTICOIDS; HISTONE DEACETYLASES; HORMONES; HUMANS; MALE; PPAR GAMMA; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ANDROGEN; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RETINOIDS; SIGNAL TRANSDUCTION; TRETINOIN; VITAMIN D;

EID: 12344265073     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.10.006     Document Type: Article

References (106)

1. B. Lytton Prostate cancer: a brief history and the discovery of hormonal ablation treatment J. Urol. 165 2001 1859 1862
2. D.L. Trump, D.C. Smith, D. Stiff, A. Adedoyin, R. Day, R.R. Bahnson, J. Hofacker, and R.A. Branch A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis Cancer Chemother. Pharmacol. 39 1997 349 356
3. S. Culine, A. Kramar, J.P. Droz, and C. Theodore Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer J. Urol. 161 1999 173 175
4. W.K. Kelly, I. Osman, V.E. Reuter, T. Curley, W.D. Heston, D.M. Nanus, and H.I. Scher The development of biologic end points in patients treated with differentiation agents: an experience of retinoids in prostate cancer Clin. Cancer Res. 6 2000 838 846
5. M. Shalev, T.C. Thompson, A. Frolov, S.M. Lippman, W.K. Hong, H. Fritsche, and D. Kadmon Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy Clin. Cancer Res. 6 2000 3845 3849
6. M. Fakih, C.S. Johnson, and D.L. Trump Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review Urology 60 2002 553 561
7. K. Akakura, H. Suzuki, T. Ueda, A. Komiya, T. Ichikawa, T. Igarashi, and H. Ito Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6 Prostate 56 2003 106 109
8. G.P. Risbridger, J.J. Bianco, S.J. Ellem, and S.J. McPherson Oestrogens and prostate cancer Endocr. Relat. Cancer 10 2003 187 191
9. H.P. Koeffler Peroxisome proliferator-activated receptor gamma and cancers Clin. Cancer Res. 9 2003 1 9
10. A.V. Krishnan, D.M. Peehl, and D. Feldman Inhibition of prostate cancer growth by Vitamin D: regulation of target gene expression J. Cell. Biochem. 88 2003 363 371
11. kip1 and E-cadherin J. Mol. Endocrinol. 19 1997 15 27
12. P. Banerjee, and M. Chatterjee Antiproliferative role of vitamin D and its analogs-a brief overview Mol. Cell. Biochem. 253 2003 247 254
13. kip1 stabilization and Cdk2 mislocalization to the cytoplasm J. Biol. Chem. 278 2003 46862 46868
14. C.S. Johnson, P.A. Hershberger, R.J. Bernardi, T.F. McGuire, and D.L. Trump Vitamin D receptor: a potential target for intervention Urology 60 2002 123 130 (discussion, pp. 130-121)
15. C.S. Johnson, P.A. Hershberger, and D.L. Trump Vitamin D-related therapies in prostate cancer Cancer Metastasis Rev. 21 2002 147 158
16. J.R. Muindi, Y. Peng, D.M. Potter, P.A. Hershberger, J.S. Tauch, M.J. Capozzoli, M.J. Egorin, C.S. Johnson, and D.L. Trump Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel Clin. Pharmacol. Ther. 72 2002 648 659
17. T.M. Beer, D. Lemmon, B.A. Lowe, and W.D. Henner High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma Cancer 97 2003 1217 1224
18. T.M. Beer, K.M. Eilers, M. Garzotto, M.J. Egorin, B.A. Lowe, and W.D. Henner Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer J. Clin. Oncol. 21 2003 123 128
19. 3 Mol. Endocrinol. 9 1995 1814 1824
20. D.J. Bettoun, T.P. Burris, K.A. Houck, D.W. Buck 2nd, K.R. Stayrook, B. Khalifa, J. Lu, W.W. Chin, and S. Nagpal Retinoid X receptor is a nonsilent major contributor to vitamin d receptor-mediated transcriptional activation Mol. Endocrinol. 17 2003 2320 2328
21. T.R. Evans, and S.B. Kaye Retinoids: present role and future potential Br. J. Cancer 80 1999 1 8
22. C.J. Fong, D.M. Sutkowski, E.J. Braun, K.D. Bauer, E.R. Sherwood, C. Lee, and J.M. Kozlowski Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells J. Urol. 149 1993 1190 1194
23. D.M. Peehl, S.T. Wong, and T.A. Stamey Vitamin A regulates proliferation and differentiation of human prostatic epithelial cells Prostate 23 1993 69 78
24. M. Esquenet, J.V. Swinnen, W. Heyns, and G. Verhoeven Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate Prostate 28 1996 182 194
25. D.M. Peehl, G.K. Leung, and S.T. Wong Keratin expression: a measure of phenotypic modulation of human prostatic epithelial cells by growth inhibitory factors Cell Tissue Res. 277 1994 11 18
26. R. Walls, A. Thibault, L. Liu, C. Wood, J.M. Kozlowski, W.D. Figg, M.L. Sampson, R.J. Elin, and D. Samid The differentiating agent phenylacetate increases prostate-specific antigen production by prostate cancer cells Prostate 29 1996 177 182
27. K. Goossens, M. Esquenet, J.V. Swinnen, M. Manin, W. Rombauts, and G. Verhoeven Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells Mol. Cell. Endocrinol. 155 1999 9 18
28. H. Huynh, M. Pollak, and J.C. Zhang Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089 Int. J. Oncol. 13 1998 137 143
29. T. Nickerson, and H. Huynh Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins J. Endocrinol. 160 1999 223 229
30. B.J. Boyle, X.Y. Zhao, P. Cohen, and D. Feldman Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1 J. Urol. 165 2001 1319 1324
31. 3 is accompanied by an increase in insulin-like growth factor binding protein-3 J. Endocrinol. 170 2001 609 618
32. K.W. Lee, and P. Cohen Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3 J. Endocrinol. 175 2002 33 40
33. 3 on prostatic epithelial cells Urol. Oncol. 1 1995 188 294
34. 3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1 Endocrinology 138 1997 1491 1497
35. 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells Endocrinology 140 1999 1205 1212
36. 3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells Prostate 40 1999 141 149
37. 3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells Mol. Cancer Ther. 2 2003 739 746
38. K. Slawin, D. Kadmon, S.H. Park, P.T. Scardino, M. Anzano, M.B. Sporn, and T.C. Thompson Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras + myc-induced carcinomas in the mouse prostate reconstitution model system Cancer Res. 53 1993 4461 4465
39. M. Igawa, T. Tanabe, G.W. Chodak, and D.B. Rukstalis N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells Prostate 24 1994 299 305
40. K.M. Roberson, S.N. Penland, G.M. Padilla, R.S. Selvan, C.S. Kim, R.L. Fine, and C.N. Robertson Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells Cell. Growth Differ. 8 1997 101 111
41. T.C. Hsieh, and J.M. Wu Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression Prostate 33 1997 97 104
42. M.S. Lucia, M.A. Anzano, M.V. Slayter, M.R. Anver, D.M. Green, M.W. Shrader, D.L. Logsdon, C.L. Driver, C.C. Brown, and C.W. Peer Chemopreventive activity of tamoxifen, N-(4-hydroxyphenyl)retinamide, and the vitamin D analogue Ro24-5531 for androgen-promoted carcinomas of the rat seminal vesicle and prostate Cancer Res. 55 1995 5621 5627
43. D.L. McCormick, K.V. Rao, L. Dooley, V.E. Steele, R.A. Lubet, G.J. Kelloff, and M.C. Bosland Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats Cancer Res. 58 1998 3282 3288
44. P. Greenwald, G. Kelloff, C. Burch-Whitman, and B.S. Kramer Chemoprevention CA Cancer J. Clin. 45 1995 31 49
45. 3 analogue and anti-activator protein 1 retinoid Br. J. Cancer 79 1999 101 107
46. R. Umbas, W.B. Isaacs, P.P. Bringuier, H.E. Schaafsma, H.F. Karthaus, G.O. Oosterhof, F.M. Debruyne, and J.A. Schalken Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer Cancer Res. 54 1994 3929 3933
47. P.J. Richmond, A.J. Karayiannakis, A. Nagafuchi, A.V. Kaisary, and M. Pignatelli Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival Cancer Res. 57 1997 3189 3193
48. T. Okegawa, Y. Li, R.C. Pong, and J.T. Hsieh Cell adhesion proteins as tumor suppressors J. Urol. 167 2002 1836 1843
49. 3 signalling Nature 355 1992 446 449
50. K. Prufer, and J. Barsony Retinoid X receptor dominates the nuclear import and export of the unliganded vitamin D receptor Mol. Endocrinol. 16 2002 1738 1751
51. T. Kikugawa, N. Tanji, T. Miyazaki, and M. Yokoyama Immunohistochemical study of the receptors for retinoic acid in prostatic adenocarcinoma Anticancer Res. 20 2000 3897 3902
52. 3 analog Endocrinology 139 1998 1972 1980
53. 3 in NRP-152 rat prostatic epithelial cells J. Cell. Physiol. 166 1996 231 239
54. 3 response elements in the human transforming growth factor beta 2 gene Biochemistry 38 1999 2654 2660
55. K. Prufer, C. Schroder, K. Hegyi, and J. Barsony Degradation of RXRs influences sensitivity of rat osteosarcoma cells to the antiproliferative effects of calcitriol Mol. Endocrinol. 16 2002 961 976
56. X.Y. Zhao, T.R. Eccleshall, A.V. Krishnan, C. Gross, and D. Feldman Analysis of vitamin D analog-induced heterodimerization of vitamin D receptor with retinoid X receptor using the yeast two-hybrid system Mol. Endocrinol. 11 1997 366 378
57. 3-dependent signal transduction by phosphorylating human retinoid X receptor alpha J. Clin. Invest. 103 1999 1729 1735
58. C. Solomon, M. Sebag, J.H. White, J. Rhim, and R. Kremer Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes J. Biol. Chem. 273 1998 17573 17578
59. D. Gioeli, J.W. Mandell, G.R. Petroni, H.F. Frierson Jr., and M.J. Weber Activation of mitogen-activated protein kinase associated with prostate cancer progression Cancer Res. 59 1999 279 284
60. M. Royuela, M.I. Arenas, F.R. Bethencourt, M. Sanchez-Chapado, B. Fraile, and R. Paniagua Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate Hum. Pathol. 33 2002 299 306
61. A. Krishnan, and D. Feldman Regulation of vitamin D receptor abundance D. Feldman F. Glorieux J.W. Pike Vitamin D 1997 Academic Press San Diego 179 200
62. G.R. Cunha, A.A. Donjacour, P.S. Cooke, S. Mee, R.M. Bigsby, S.J. Higgins, and Y. Sugimura The endocrinology and developmental biology of the prostate Endocr. Rev. 8 1987 338 362
63. I. Leav, J.E. McNeal, P.W. Kwan, P. Komminoth, and F.B. Merk Androgen receptor expression in prostatic dysplasia (prostatic intraepithelial neoplasia) in the human prostate: an immunohistochemical and in situ hybridization study Prostate 29 1996 137 145
64. D.M. Peehl, and R.G. Sellers Cultured stromal cells: an in vitro model of prostatic mesenchymal biology Prostate 45 2000 115 123
65. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat. Rev. Cancer 1 2001 34 45
66. 3 in the androgen-dependent LNCaP cells Biochem. Biophys. Res. Commun. 223 1996 141 146
67. 3 in androgen-responsive LNCaP cells Biochem. Biophys. Res. Commun. 235 1997 539 544
68. 3 actions in LNCaP human prostate cancer cells are androgen-dependent Endocrinology 138 1997 3290 3298
69. A.V. Krishnan, R. Shinghal, N. Raghavachari, J.D. Brooks, D.M. Peehl, and D. Feldman Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays Prostate 59 2004 243 251
70. 3 in prostate cancer cells J. Steroid Biochem. Mol. Biol. 85 2003 1 8
71. J.V. Swinnen, T. Roskams, S. Joniau, H. Van Poppel, R. Oyen, L. Baert, W. Heyns, and G. Verhoeven Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer Int. J. Cancer 98 2002 19 22
72. J.L. Martin, and S.L. Pattison Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells Endocrinology 141 2000 2401 2409
73. 3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells J. Cell. Biochem. 88 2003 609 622
74. C. Crescioli, P. Ferruzzi, A. Caporali, R. Mancina, A. Comerci, M. Muratori, M. Scaltriti, G.B. Vannelli, S. Smiroldo, R. Mariani, D. Villari, S. Bettuzzi, M. Serio, L. Adorini, and M. Maggi Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog Endocrinology 144 2003 3046 3057
75. E.S. Leman, J.A. Arlotti, R. Dhir, and R.H. Getzenberg Vitamin D and androgen regulation of prostatic growth J. Cell. Biochem. 90 2003 138 147
76. D. Krill, J. Stoner, B.R. Konety, M.J. Becich, and R.H. Getzenberg Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture Urology 54 1999 171 177
77. 3 on primary cultures of human prostatic cells Cancer Res. 54 1994 805 810
78. B.R. Konety, A.K. Nangia, T.S. Nguyen, A. Thomas, and R.H. Getzenberg Effect of prenatal vitamin D (calcitriol) exposure on the growth and development of the prostate Prostate 41 1999 181 189
79. G.S. Prins, L. Birch, J.F. Couse, I. Choi, B. Katzenellenbogen, and K.S. Korach Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor alpha: studies with alphaERKO and betaERKO mice Cancer Res. 61 2001 6089 6097
80. B.R. Konety, E. Leman, B. Vietmeier, J. Arlotti, R. Dhir, and R.H. Getzenberg In vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate J. Urol. 164 2000 1812 1818
81. B.R. Konety, G.G. Schwartz, J.S. Acierno Jr., M.J. Becich, and R.H. Getzenberg The role of vitamin D in normal prostate growth and differentiation Cell. Growth Differ. 7 1996 1563 1570
82. 3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms Endocrinology 141 2000 2548 2556
83. E.S. Yang, C.A. Maiorino, B.A. Roos, S.R. Knight, and K.L. Burnstein Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer Mol. Cell. Endocrinol. 186 2002 69 79
84. 3 Prostate 56 2003 293 304
85. M. Koutsilieris, C. Reyes-Moreno, A. Sourla, V. Dimitriadou, and I. Choki Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer Anticancer Res. 17 1997 1461 1465
86. K. Nishimura, N. Nonomura, E. Satoh, Y. Harada, M. Nakayama, T. Tokizane, T. Fukui, Y. Ono, H. Inoue, M. Shin, Y. Tsujimoto, H. Takayama, K. Aozasa, and A. Okuyama Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer J. Natl. Cancer Inst. 93 2001 1739 1746
87. J.L. Mohler, Y. Chen, K. Hamil, S.H. Hall, J.A. Cidlowski, E.M. Wilson, F.S. French, and M. Sar Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma Clin. Cancer Res. 2 1996 889 895
88. D.M. Peehl, and T.A. Stamey Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone Prostate 8 1986 51 61
89. A.V. Krishnan, X.Y. Zhao, S. Swami, L. Brive, D.M. Peehl, K.R. Ely, and D. Feldman A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer Endocrinology 143 1992 1889 1900
90. J. Veldscholte, C.A. Berrevoets, C. Ris-Stalpers, G.G. Kuiper, G. Jenster, J. Trapman, A.O. Brinkmann, and E. Mulder The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens J. Steroid Biochem. Mol. Biol. 41 1992 665 669
91. M.E. Taplin, G.J. Bubley, Y.J. Ko, E.J. Small, M. Upton, B. Rajeshkumar, and S.P. Balk Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist Cancer Res. 59 1999 2511 2515
92. C.Y. Chang, P.J. Walther, and D.P. McDonnell Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer Cancer Res. 61 2001 8712 8717
93. L.G. Raisz, and B.P. Lukert Glucocorticoid and vitamin D interactions D. Feldman F.H. Glorieux J.W. Pike Vitamin D 1997 Academic Press San Diego 789 796
94. I.M. Byrne, L. Flanagan, M.P. Tenniswood, and J. Welsh Identification of a hormone-responsive promoter immediately upstream of exon 1c in the human vitamin D receptor gene Endocrinology 141 2000 2829 2836
95. 3-mediated antitumor activity with dexamethasone J. Natl. Cancer Inst. 90 1998 134 141
96. S. Ahmed, C.S. Johnson, R.M. Rueger, and D.L. Trump Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/ dexamethasone in an androgen independent prostate cancer model J. Urol. 168 2002 756 761
97. R.J. Bernardi, D.L. Trump, W.D. Yu, T.F. McGuire, P.A. Hershberger, and C.S. Johnson Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: role of nuclear receptor cross-talk and Erk/Akt signaling Clin. Cancer Res. 7 2001 4164 4173
98. T. Kubota, K. Koshizuka, E.A. Williamson, H. Asou, J.W. Said, S. Holden, I. Miyoshi, and H.P. Koeffler Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Res. 58 1998 3344 3352
99. Y. Xu, S. Iyengar, R.L. Roberts, S.B. Shappell, and D.M. Peehl Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells J. Cell. Physiol. 196 2003 131 143
100. N.J. McKenna, J. Xu, Z. Nawaz, S.Y. Tsai, M.J. Tsai, and B.W. O'Malley Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions J. Steroid Biochem. Mol. Biol. 69 1999 3 12
101. S.F. Rashid, J.S. Moore, E. Walker, P.M. Driver, J. Engel, C.E. Edwards, G. Brown, M.R. Uskokovic, and M.J. Campbell Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A Oncogene 20 2001 1860 1872
102. A.I. Spira, and M.A. Carducci Differentiation therapy Curr. Opin. Pharmacol. 3 2003 338 343
103. M. Boudjelal, Z. Wang, J.J. Voorhees, and G.J. Fisher Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes Cancer Res. 60 2000 2247 2252
104. H. Masuyama, and P.N. MacDonald Proteasome-mediated degradation of the vitamin D receptor (VDR) and a putative role for SUG1 interaction with the AF-2 domain of VDR J. Cell. Biochem. 71 1998 429 440
105. J. Adams, V.J. Palombella, and P.J. Elliott Proteasome inhibition: a new strategy in cancer treatment Hum. Pathol. 18 2000 109 121
106. S. Williams, C. Pettaway, R. Song, C. Papandreou, C. Logothetis, and D.J. McConkey Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts Mol. Cancer Ther. 2 2003 835 843